Exelixis | EXEL - Market Capitalization


Exelixis reported $15.84B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 195.44B 5.55B Jun/2026
AstraZeneca USD 289.99B 11.26B Jun/2026
Bayer EUR 47.56B 8.87B Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Cytokinetics USD 11.55B 3.36B Jun/2026
Eisai JPY 1.2T 219.32B Jun/2026
Eli Lilly USD 1.13T 260.54B Jun/2026
Exelixis USD 13.54B 2.65B Jun/2026
Genmab DKK 17.1B 88.06B Jun/2026
Glaxosmithkline GBP 109.29B 9.36B Mar/2026
Incyte USD 22.65B 3.92B Jun/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
MacroGenics USD 184M 82M Mar/2026
Merck USD 317.37B 20.27B Jun/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Pfizer USD 138.44B 15.37B Jun/2026
Sanofi EUR 113.52B 3.82B Mar/2026
Takeda JPY 8.2T 809.7B Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Xencor USD 1.19B 301M Jun/2026